OUR
LEADERSHIP
-
SIZHEN
WANGCO-FOUNDER ,
CHAIRMAN AND CHIEF
EXECUTIVE OFFICER -
YUNFU
HUCHIEF MEDICAL
OFFICER
-
YUCHEN
JIAOCHIEF TECHNOLOGY
OFFICER -
VICTORIA
LEICHIEF OPERATING
OFFICER
-
TODD
LIANGCHIEF HUMAN
RESOURCES OFFICER -
EVAN
XUCHIEF FINANCIAL
OFFICER
-
ZHAOHUI
YINVICE
PRESIDENT -
CATHY
ZHANGVICE
PRESIDENT
With extensive
entrepreneurial experience across multiple disciplines and corporate
management capabilities, Sizhen Wang leads Genetron Health in consistently
exploring cancer genomics and promoting bio-innovative technology
applications, in order to further the development of human health.
Sizhen Wang
Co-founder , Chairman And Chief Executive Officer
Sizhen co-founded Genetron Health in 2013, which at present has become
a leading precision oncology platform company in China. It was listed on
Nasdaq (GTH) in June 2020 and became the largest precision oncology IPO
in the world at that time. With the service portfolio of "cancer early
screening + cancer diagnosis and monitoring + biopharma services",
Genetron Health has served the top hospitals and physical
examination institutions, dozens of pharmaceutical enterprises and
scientific research institutions in China, and participated in a number
of government livelihood projects and social welfare projects.In 2021,
under Sizhen’s leadership, Genetron Health’s early precision lung cancer
diagnosis and treatment project, a joint initiative with the West China
Hospital of Sichuan University, won the second prize of China’s National
Science and Technology Progress Award.
In 2004, Sizhen co-founded iTalkBB, a company providing global
telephone, TV, data and mobile communication services to millions of
users around the world. iTalkBB is now the leading Internet
communications brand among Chinese communities in North America and
Australia.
Sizhen also has ten years of experience working in the finance
industry, including at Capital One and GD Capital.
Sizhen graduated from the HEC Paris School of Management with an MBA
degree.
Evan Xu spent more
than 12 years in international investment banks, with extensive experience
in corporate finance and M&A. He previously held the sponsor principal
license granted by Securities and Futures Commission, Hong Kong.
Evan Xu
Chief Financial Officer
Evan helped Genetron Health successfully listed in Nasdaq, as the
largest IPO of precision oncology globally by then.
Evan previously served as a Director of Investment Banking Division at
Deutsche Bank AG, Hong Kong.
Evan served as Executive Director of the Investment Banking Division
at Goldman Sachs (Asia) L.L.C in Hong Kong.
Evan served as an analyst and associate at Lehman Brothers and Nomura
Securities in Hong Kong.
Evan obtained a Master's degree from the National University of
Singapore.
During her career,
Victoria Lei has contributed to the success of several Fortune 500
companies, earning awards for her excellent management skills. Additionally,
Victoria is a successful entrepreneur with extensive management experience
spanning more than 20 years throughout
North America, Australia and Asia.
Victoria Lei
CHIEF OPERATING OFFICER
Victoria is a visionary global business leader who is adept at formulating and executing innovative business strategies. She has consistently demonstrated strong leadership skills and market expansion capabilities.
Victoria has comprehensive experience in bringing high-tech products
from concept to market. Her leadership experience encompasses the entire
process of guiding new products from concept design, achieving scale and
operational standardization, to implementation and market
promotion.
Victoria holds a bachelor’s degree in management from the University
of South Carolina and the Hotel Institute Montreux, Switzerland. She
successfully completed the General Management Program of the Harvard
Business School.
Cathy Zhang has
profound experience in overseas business development and team management.
She has worked for multinational companies (Fortune 500 companies) for over
three decades.
Cathy Zhang
Vice President
Cathy previously worked as the director of sales and government
affairs, as well as vice president of overseas markets at
Alcatel.
Cathy previously led the overseas business development at
Alcatel-Lucent Shanghai Bell.
Cathy previously worked for HP China and Ericsson.
Cathy graduated from Fudan University School of Management, and
obtained her International MBA from University of Hong Kong.
Lin Teng has over
two decades of experience working in the pharmaceutical industry, includes
over 15 years of management experience with oncology companies.
Lin Teng
Vice President
Lin is experienced in team management and resource integration. Her
strong leadership lead the business team rapidly develop and gain more
market share in the tumor molecular diagnosis sector. She also has
in-depth and unique insights into all aspects of the tumor ecological
chain, including diagnosis and treatment.
Lin has served at Roche and Eli-Lilly China.
Lin obtained an EMBA from China Europe International Business School
(CEIBS), and a bachelor’s degree in Medicine from Shandong
University.
Zhaohui Yin has over
25 years of experience in commerce, sales and management in health care, all
of which rank among the top 10 pharmaceutical enterprises globally. He has
extensive experience in the fields of IVD, gene sequencing and related
equipment or high-value supplements, particularly in building a
comprehensive dealer system from scratch, with successful experience in
graded sales management.
Zhaohui Yin
Vice President
Zhaohui previously served as Deputy General Manager of Guangzhou Darui
Biotechnology Co. Ltd. Under his leadership, Guangzhou Darui
Biotechnology Co. Ltd. became a leading enterprise focused on
reproductive health in the field of genetic testing. He founded the
overseas testing company Ruikang International and served as General
Manager, establishing the company’s operating team and doubling its
revenue.
Zhaohui previously served as the business and sales director at
Becton, Dickinson and Company, as well as Abbott.
Zhaohui has held sales and management positions at Johnson & Johnson
and GSK.
Zhaohui is a licensed anesthesiologist.
Zhaohui obtained bachelor degree of clinical medicine from the
Southeast University, and was a visiting scholar at the School of
Medicine, Stanford University.
Yuchen Jiao
studied the cancer genomics of various tumors, and identified novel tumor
suppressor genes including ATRX, which were listed as an important
diagnostic marker by the WHO classification of tumors of the central nervous
system.
Yuchen Jiao
Chief Technology Officer
Yuchen published more than 20 research papers in Science, Nature
Genetics, PNAS and other journals as first or corresponding
author.
Yuchen finished his postdoctoral training in the team of Professor
Bert Vogelstein.
Yuchen received his M.D. in clinical medicine from Peking Union
Medical College and his Ph.D. degree in biological chemistry at the
Johns Hopkins University.
Yunfu Hu has more
than two decades of experience in regulatory and business management related
to medical devices and pharmaceutical R&D industries.
Yunfu Hu
Chief Medical Officer
Under Yunfu’s leadership, Genetron Health’s blood-based
next-generation sequencing (NGS) test, HCCscreen™️, received
Breakthrough Device designation from the U.S. Food and Drug
Administration (FDA), which made it the first product in China's
molecular diagnostic industry to achieve this recognition.
Yunfu previously served as Deputy Director of the Division of
Molecular Genetics and Pathology in the Office of In Vitro Diagnostics
and Radiological Health, Center for Devices and Radiological Health at
FDA. He was responsible for supervising in vitro diagnostic products
such as cancer molecular diagnosis, companion diagnostic products, gene
testing, artificial intelligence in pathology and cytological
detection.
Some of Yunfu’s notable FDA approvals include: Myriad Genetics' BRAC
Analysis CDx; Foundation Medicine's FoundationFocus CDxBRCA;
ThermoFisher Oncomine Dx Target Test; FoundationOne CDx; Roche Cobas
EGFR Mutation Test v2; Exact Sciences’ Cologuard and Epigenomics’ Epi
ProColon.
Yunfu has 10 years of product development experience with world-class
diagnostic and pharmaceutical companies. He has made outstanding
achievements in precision medical research, tumor biomarker development
and diagnostic product development and registration.
Yunfu obtained his Ph.D. in Veterinary Physiology & Pharmacology and
Master’s degree in Reproductive Endocrinology at Ohio State University.
He was Postdoctoral Fellow of Fox Chase Cancer Center.
Todd Liang has
more than 20 years of management experience in HR development. He has worked
as head of HR at multinational companies from Europe and the U.S., as well
as at internet start-ups, and local holding companies in China. He has
experience across various industries including fast-moving consumer goods,
e-commerce, real-estate, hospitality and education.
Todd Liang
Chief Human Resources Officer
Todd has served as Chief Human Resources Officer of OneSmart Education
Group; Vice President of Wanda Hotel Group; Human Resources Vice
President of YHD.com; Human Resources Director of Asia Pacific Region of
SSL Group; and Human Resources Manager of GE Plastics Greater China.
Over the course of his career, Todd led HR teams to sufficiently support
fast business growth by strengthening talent and organizational
capabilities.
Todd obtained an EMBA from China Europe International Business School
(CEIBS), and a B.A. from Southwest Jiaotong University.
CONTACT US